Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	8/10/2006 1:07:52 PM
	Read Replies (1) of 52153

Wow! Too bad this is only a Phase I. 8:20AM Sirna Therapeutics: 100% visual acuity stabilization observed in all patient groups eight weeks after a single dose of Sirna-027 (RNAI) 4.42 : Co announces the final results from its recently completed Phase 1 trial for Sirna-027, a novel therapeutic for age-related macular degeneration. Single ascending doses of Sirna-027 were safe and well tolerated, and all 26 patients showed visual acuity stabilization eight weeks after a single injection. In addition, at the same time point, five of 26 patients (19%) experienced clinically significant improvement in visual acuity, indicated by an increase of at least three lines on an eye chart.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next